SMA

Semaglutide is a synthetic GLP-1 receptor agonist with 94% homology to endogenous GLP-1. It has been structurally modified to resist dipeptidyl peptidase-4 (DPP-4) degradation and to enhance albumin binding, extending its half-life to approximately 165 hours. This enables once-weekly subcutaneous dosing (Ozempic® for type 2 diabetes, Wegovy® for obesity) or daily oral dosing (Rybelsus®).

Glycemic Control: HbA1c reduction of 1.5–2.2%; 60–70% achieving HbA1c <7%
Weight Loss: Mean 15.2% body weight reduction; 40% losing ≥20%
Cardiovascular Protection: 26% reduction in major CV events; improved endothelial function
Appetite Suppression: Central GLP-1 receptor activation reduces caloric intake
Insulin Sensitivity: Improved HOMA-IR; maintains β-cell function
Convenient Dosing: Once-weekly subcutaneous or daily oral administration
Multi-Organ Benefits: Kidney, liver, and potential neuroprotection
Safety Profile: Mild-to-moderate GI side effects, usually resolving with dose titration
Sustained Efficacy: Long-term weight and glycemic control maintained for up to 2 years

Davies, M., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet, 397(10278), 971-984. DOI: 10.1016/S0140-6736(21)00213-0
Garvey, W.T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. DOI: 10.1038/s41591-022-02026-4
Marso, S.P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM, 375(19), 1834-1844. DOI: 10.1056/NEJMoa1607141
Nauck, M.A., et al. (2019). Semaglutide vs dulaglutide once weekly (SUSTAIN 7). Lancet Diabetes & Endocrinology, 7(10), 776-785. DOI: 10.1016/S2213-8587(19)30224-X
Rubino, D., et al. (2021). Continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 325(14), 1414-1425. DOI: 10.1001/jama.2021.3224

$120.00

Per Unit

In stock